Clinical trial NCT04854330: Ketone Esters in T2DM
Official title: The Acute Effect of Ketone Esters on Energy Metabolism, Cardiorespiratory Fitness and Cardiovascular Health in People With Type 2 Diabetes Mellitus.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 2 Diabetes
Lead sponsor: University of Portsmouth
Sponsor class: OTHER
Collaborators: name: Portsmouth Hospitals NHS Trust
First posted: 2021-04-22
Enrollment: 16
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: The proposed study design will be a randomised placebo-controlled, double-blind, crossover study.
Primary purpose: OTHER

Brief summary: Type 2 diabetes mellitus (T2DM) reduces the ability of the body to use sugar as a fuel. As an alternative people with T2DM can use fat from the blood stream instead. Fat is a good store of energy, however, the body requires about 20% more oxygen to produce energy from fat compared to sugar. People with T2DM often have heart disease as well. This can lead to limited availability of oxygen in the heart muscle, which increases the workload of the heart and will impact on the ability to perform everyday tasks, such as walking up a flight of steps. Recently, it has been suggested that ketone esters (a sports drink that contains ketones) may be used as an alternative source of energy for people with diabetes as they are approximately 8% more efficient than fat. The investigators will assess whether these ketones can be used as a more efficient source of energy and improve how the heart works in people with T2DM. If successful, this is a relatively cheap treatment, which could be immediately implemented in people with T2DM to improve heart function and the ability to perform everyday tasks.

Detailed description: Type 2 diabetes mellitus (T2DM) is a chronic and progressive metabolic disease associated with an increased prevalence of cardiovascular events, and therefore represents a significant global health concern. The aetiology of the disease is complex and involves the interaction of both non-modifiable (i.e., genetic predisposition) and modifiable (e.g., physical activity levels, diet, body mass) risk factors. Individuals with T2DM have an impaired ability to utilise glucose, the body's most efficient energy substrate (providing 2.58 ATP per molecule of oxygen), due to a decreased capacity to produce and/or utilise insulin. Consequently, there is an increased reliance on the metabolism of less efficient fuel sources, predominantly the metabolism of the free fatty acid palmitate, which produces 2.33 ATP per molecule of oxygen and thereby increases oxygen requirements by approximately 10% relative to glucose metabolism. This increased oxygen cost that manifests at rest and during exercise, increases the effort required to perform physical tasks which may discourage physical activity, further exacerbating the disease state and the prevalence of associated cardiovascular co-morbidities, and may ultimately reduce quality of life.

Whereas at high concentrations, ketone bodies are known to be toxic, at a low dose ß hydroxybutyrate, one of the most common ketone bodies produced, can be used as a metabolic substrate. Although not an efficient store of energy per se, the energy can be released at a lower O2 cost than free fatty acids, generating 2.50 units of ATP per unit of O2 consumed. Theoretically, this 7% improvement in efficiency would be of benefit to those with heart disease and diabetes. Whilst there are several studies demonstrating the theoretical benefit of this improvement in efficiency in vitro or in animal models, to date this has not been demonstrated in humans.

Sodium glucose transporter 2 (SGLT-2) inhibitors, a class of anti-hyperglycaemic agents, have been shown to suppress insulin production whilst stimulating glucagon, an action that engenders mild hyperketonaemia. Interestingly, recent trials have suggested the use of SGLT-2 inhibitors have a cardio-protective effect indicated by a significant reduction in cardiovascular related death in people with type 2 diabetes. It is hypothesised that this benefit is mediated through alternate substrate utilisation. These medications, however cannot be used for all individuals. They are not licensed for, nor are likely to be effective for people with impaired renal function, which is common among people with heart failure and diabetes. The associated risk of genital infections is over 10% even in those who have been prescribed the SGLT-2 inhibitors medication.

Exogenous ketone supplements can be ingested in the form of ketone esters and have been proven efficient in improving metabolic profile by decreasing circulating glucose and free fatty acids. More specifically a ketone monoester (Kme) supplement has been shown to provide a rapid increase in blood ß-hydroxybutyrate levels within 30 min in healthy humans. Importantly, once ingested, Kme is metabolised into ß-hydroxybutyrate, which is the isoform produced by endogenous ketogenesis. Therefore, the oral consumption of Kme may be an interesting alternative for increasing ß hydroxybutyrate and therefore improving metabolic efficiency and cardiovascular function in individuals with T2DM.

Eligibility criteria: Inclusion Criteria:

• HbA1c \> 48 mmol/mol

Exclusion Criteria:

* they present with severe renal impairment (eGFR \< 30ml/min)
* they use concomitantly GLP-1 Receptor agonists (which reduce glucagon and therefore hydroxybutyrate production);
* they currently participating in a very low calorie diet or restricted carbohydrate diet (which artificially increase endogenous ketone production);
* they present uncontrolled hypertension (systolic blood pressure \> 180 mmHg);
* they have a history of myocardial infarction or cerebro-vascular events in the last 3 months;
* have a a BMI \> 40 kg/m2;
* they are unable to exercise;
* they have an allergy or intolerance to ketone esters ;
* they are unable to give informed consent
* have any other serious medical condition which in the opinion of study investigators would interfere with safety or data interpretation.

Primary outcomes:
measure: Cardiac output
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
Secondary outcomes:
measure: Fuel utilisation test
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
measure: Exercise capacity and fuel utilisation during exercise test
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
measure: Near infrared spectrometry (NIRS)
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
measure: Ketone concentration
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
measure: Troponin concentration
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
measure: IL6 concentration
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
measure: IL10 concentration
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
measure: VEGF
timeFrame: Crossover design. Assessed once on placebo and Ketone esters ~7 days apart
Other outcomes:
Locations:
Study officials:
References: